References
Centers for Disease Control and Prevention (CDC). Vital signs: prevalence, treatment, and control of hypertension--United States, 1999–2002 and 2005–2008. MMWR Morb Mortal Wkly Rep. 2011;4(60):103–8.
Chobanian A, Bakris G, Black H, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42:1206–52.
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981–97.
Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al. ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet. 2005;366:895–906.
Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V, et al. ACCOMPLISH trial investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359:2417–28.
Weber MA, Julius S, Kjeldsen SE, Brunner HR, Ekman S, Hansson L, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet. 2004;363:2049–51.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Siragy, H.M. To ACCELERATE Hypertension Control. Curr Hypertens Rep 13, 259–261 (2011). https://doi.org/10.1007/s11906-011-0203-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11906-011-0203-1